Exelixis Appoints New Chief Medical and Scientific Officers
Ticker: EXEL · Form: 8-K · Filed: Mar 29, 2024 · CIK: 939767
Sentiment: neutral
Topics: executive-appointment, leadership-change, r&d
Related Tickers: BMY
TL;DR
Exelixis beefs up R&D with new CMO & CSO from BMS and internal promotion.
AI Summary
Exelixis, Inc. announced on March 27, 2024, the appointment of Dr. Michelle Werner as Chief Medical Officer and Dr. Peter Lamb as Chief Scientific Officer. Dr. Werner previously served as Executive Vice President, Head of Oncology at Bristol Myers Squibb, and Dr. Lamb was previously Executive Vice President, Head of Research and Development at Exelixis. These appointments are effective immediately.
Why It Matters
The appointment of experienced executives in key scientific and medical roles signals a strategic shift or reinforcement of Exelixis's research and development pipeline, potentially impacting future drug development and clinical trial success.
Risk Assessment
Risk Level: medium — Changes in key executive leadership, especially in scientific and medical roles, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Exelixis, Inc. (company) — Registrant
- Dr. Michelle Werner (person) — Appointed Chief Medical Officer
- Dr. Peter Lamb (person) — Appointed Chief Scientific Officer
- Bristol Myers Squibb (company) — Previous employer of Dr. Werner
- March 27, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer at Exelixis?
Dr. Michelle Werner has been appointed as the new Chief Medical Officer.
What was Dr. Michelle Werner's previous role?
Dr. Michelle Werner's previous role was Executive Vice President, Head of Oncology at Bristol Myers Squibb.
Who is the new Chief Scientific Officer at Exelixis?
Dr. Peter Lamb has been appointed as the new Chief Scientific Officer.
What was Dr. Peter Lamb's previous role within Exelixis?
Dr. Peter Lamb was previously Executive Vice President, Head of Research and Development at Exelixis.
When were these executive appointments effective?
These appointments were effective as of March 27, 2024.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-03-29 16:14:31
Key Financial Figures
- $0.001 — hange on which registered Common Stock $0.001 Par Value per Share EXEL The Nasdaq Sto
Filing Documents
- exel-20240327.htm (8-K) — 21KB
- exel-20240327_g1.jpg (GRAPHIC) — 54KB
- 0000939767-24-000040.txt ( ) — 272KB
- exel-20240327.xsd (EX-101.SCH) — 2KB
- exel-20240327_lab.xml (EX-101.LAB) — 21KB
- exel-20240327_pre.xml (EX-101.PRE) — 12KB
- exel-20240327_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. E XELIXIS, I NC. March 29, 2024 /s/ Jeffrey J. Hessekiel Date Jeffrey J. Hessekiel Executive Vice President, General Counsel and Secretary